We are live on ! Find out more
JSAM

J. Safra Asset Management Portfolio holdings

AUM $2.17B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+5.53%
1 Year Est. Return
+29.66%
3 Year Est. Return
+84.26%
5 Year Est. Return
+107.54%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$61.3M
Cap. Flow
+$16M
Cap. Flow %
1.52%
Top 10 Hldgs %
75.78%
Holding
322
New
54
Increased
182
Reduced
11
Closed
24

Top Buys

Rank Stock Value
1
RSP icon
Invesco S&P 500 Equal Weight ETF
RSP
+$36.6M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$32.8M
3
GLD icon
SPDR Gold Trust
GLD
+$6.52M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.77M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$4.1M

Top Sells

Rank Stock Value
1
SMH icon
VanEck Semiconductor ETF
SMH
+$29.9M
2
QQQ icon
Invesco QQQ Trust
QQQ
+$24M
3
IJR icon
iShares Core S&P Small-Cap ETF
IJR
+$22.8M
4
IWF icon
iShares Russell 1000 Growth ETF
IWF
+$6.4M
5
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$2.65M

Sector Composition

Rank Sector Weight
1 Technology 1.16%
2 Consumer Discretionary 0.55%
3 Financials 0.43%
4 Communication Services 0.39%
5 Healthcare 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
276
10x Genomics
TXG
$7.69B
$884 ﹤0.01%
+39
New +$806
VEEV icon
277
Veeva Systems
VEEV
$38.5B
$843 ﹤0.01%
+4
New +$791
BRKR icon
278
Bruker
BRKR
$8.7B
$777 ﹤0.01%
+11
New +$711
RPRX icon
279
Royalty Pharma
RPRX
$25.9B
$733 ﹤0.01%
+26
New +$720
PRCT icon
280
Procept Biorobotics
PRCT
$1.25B
$716 ﹤0.01%
+9
New +$639
PRVA icon
281
Privia Health
PRVA
$2.81B
$705 ﹤0.01%
+39
New +$744
NUVL
282
DELISTED
Nuvalent
NUVL
$694 ﹤0.01%
+7
New +$581
MOH icon
283
Molina Healthcare
MOH
$10.2B
$684 ﹤0.01%
+2
New +$660
ALHC icon
284
Alignment Healthcare
ALHC
$2.76B
$585 ﹤0.01%
+51
New +$482
LFST icon
285
Lifestance Health
LFST
$4.38B
$541 ﹤0.01%
+78
New +$469
MRUS
286
DELISTED
Merus
MRUS
$430 ﹤0.01%
+9
New +$470
XENE icon
287
Xenon Pharmaceuticals
XENE
$6.08B
$425 ﹤0.01%
+11
New +$444
ACLX
288
DELISTED
Arcellx
ACLX
$414 ﹤0.01%
+5
New +$333
MLTX icon
289
MoonLake Immunotherapeutics
MLTX
$1.38B
$395 ﹤0.01%
+8
New +$375
DYN icon
290
Dyne Therapeutics
DYN
$4.93B
$372 ﹤0.01%
+11
New +$438
PHR icon
291
Phreesia
PHR
$769M
$364 ﹤0.01%
+16
New +$375
AGL icon
292
Agilon Health
AGL
$1.5B
$363 ﹤0.01%
4
-164
-98% -$21.2K
BNTX icon
293
BioNTech
BNTX
$23.3B
$355 ﹤0.01%
+3
New +$276
KROS icon
294
Keros Therapeutics
KROS
$209M
$339 ﹤0.01%
+6
New +$296
VRDN icon
295
Viridian Therapeutics
VRDN
$2.61B
$327 ﹤0.01%
+14
New +$229
JANX icon
296
Janux Therapeutics
JANX
$1.02B
$324 ﹤0.01%
+7
New +$305
CRGX
297
DELISTED
CARGO Therapeutics
CRGX
$244 ﹤0.01%
+14
New +$250
IMCR icon
298
Immunocore
IMCR
$1.74B
$157 ﹤0.01%
+5
New +$182
ADNT icon
299
Adient
ADNT
$1.47B
– –
-43
Closed -$1.06K
CCK icon
300
Crown Holdings
CCK
$13.1B
– –
-11
Closed -$818
9 10 11
12
13

Similar funds

ET
Entropy Technologies New York $2.17B AUM 21.46% 1-Year Est. Return
MIAS
Mason Investment Advisory Services Reston, Virginia $2.17B AUM 28.39% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
IIP
Intermede Investment Partners London, United Kingdom $2.16B AUM 18.47% 1-Year Est. Return
ORCP
One Rock Capital Partners New York $2.19B AUM
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

J. Safra Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, J. Safra Asset Management held 322 positions worth $1.05B, up 6.2% from $991M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

J. Safra Asset Management's Q3 2024 filing shows 54 new, 182 increased, 11 reduced and 24 closed positions. Its largest new stake was Quest Diagnostics: 1,087 shares worth $168K. The largest sale was VanEck Semiconductor ETF, an estimated $29.9M.

By sector, the portfolio is most concentrated in Technology at 1.2% of assets, up from 0.88% a quarter earlier, followed by Consumer Discretionary and Financials.

  • J. Safra Asset Management's largest Q3 2024 buy was Quest Diagnostics: 1,087 shares worth $168K.
  • J. Safra Asset Management added most to Invesco S&P 500 Equal Weight ETF in Q3 2024, an estimated $36.6M increase.
  • J. Safra Asset Management's biggest Q3 2024 reduction was VanEck Semiconductor ETF, cutting an estimated $29.9M.
  • J. Safra Asset Management fully exited Global X Uranium ETF in Q3 2024, selling an estimated $403K.
  • J. Safra Asset Management's ten largest holdings make up 76% of its $1.05B portfolio in Q3 2024.
  • J. Safra Asset Management opened 54 new positions and closed 24 in Q3 2024.
  • J. Safra Asset Management's portfolio value rose 6.2% quarter-over-quarter to $1.05B.

Based on J. Safra Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.